{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:21:26Z","timestamp":1790882486544,"version":"4.1.0"},"reference-count":94,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Human Pseudomonas infections have high morbidity and mortality rates. Pseudomonas bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required. Intravenous fosfomycin is being repurposed in a combination given its favorable pharmacokinetic\/pharmacodynamic properties (a small molecule with favorable kinetic both in bloodstream infection and in deep-seated infections), antibiofilm activity, and its interesting synergistic effects with other antimicrobials. Recent literature on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against Pseudomonas is herein reviewed and discussed.<\/jats:p>","DOI":"10.3390\/antibiotics12121653","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T11:31:25Z","timestamp":1700739085000},"page":"1653","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3408-4877","authenticated-orcid":false,"given":"Giuseppe","family":"Pipitone","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, ARNAS Civico-Di Cristina Hospital, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6121-7009","authenticated-orcid":false,"given":"Stefano","family":"Di Bella","sequence":"additional","affiliation":[{"name":"Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7218-7762","authenticated-orcid":false,"given":"Alberto Enrico","family":"Maraolo","sequence":"additional","affiliation":[{"name":"First Division of Infectious Diseases, Cotugno Hospital, Azienda Ospedaliera dei Colli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5796-0545","authenticated-orcid":false,"given":"Guido","family":"Granata","sequence":"additional","affiliation":[{"name":"Clinical and Research Department for Infectious Diseases, National Institute for Infectious Diseases L. Spallanzani, IRCCS, 00149 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3018-3779","authenticated-orcid":false,"given":"Milo","family":"Gatti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"},{"name":"Clinical Pharmacology Unit, IRCCS University Hospital of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2000-5322","authenticated-orcid":false,"given":"Luigi","family":"Principe","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3846-4620","authenticated-orcid":false,"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Department of Medical and Surgical Sciences, \u2018Magna Graecia\u2019 University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gizzi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, ARNAS Civico-Di Cristina Hospital, 90127 Palermo, Italy"},{"name":"Infectious Diseases Unit, University Hospital P. Giaccone, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Pallone","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, University Hospital \u201cRenato Dulbecco\u201d, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-1796","authenticated-orcid":false,"given":"Antonio","family":"Cascio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, University Hospital P. Giaccone, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Iaria","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, ARNAS Civico-Di Cristina Hospital, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections","volume":"2023","author":"Tamma","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Antonello, R.M., Principe, L., Maraolo, A.E., Viaggi, V., Pol, R., Fabbiani, M., Montagnani, F., Lovecchio, A., Luzzati, R., and Di Bella, S. (2020). Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies. Antibiotics, 9.","DOI":"10.3390\/antibiotics9080500"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1099\/jmm.0.000984","article-title":"Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa","volume":"68","author":"Avery","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"ref_4","first-page":"286","article-title":"In-vitro Effect of Imipenem, Fosfomycin, Colistin, and Gentamicin Combination against Carbapenem-resistant and Biofilm-forming Pseudomonas aeruginosa Isolated from Burn Patients","volume":"20","author":"Memar","year":"2021","journal-title":"Iran J. Pharm. Res."},{"key":"ref_5","unstructured":"Testing, E.C.o.A.S. (2023, October 02). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Available online: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_13.1_Breakpoint_Tables.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/jac\/dkv221","article-title":"In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa","volume":"70","author":"Walsh","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jhin.2007.10.016","article-title":"Long-term evolution of a nosocomial outbreak of Pseudomonas aeruginosa producing VIM-2 metallo-enzyme","volume":"68","author":"Corvec","year":"2008","journal-title":"J. Hosp. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ijantimicag.2008.05.010","article-title":"Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis","volume":"32","author":"Faruqi","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jgar.2020.02.014","article-title":"In vitro activity of fosfomycin against mucoid and non-mucoid Pseudomonas aeruginosa strains","volume":"20","author":"Bressan","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jac\/dkx483","article-title":"Antibacterial activity of ceftolozane\/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa","volume":"73","author":"Monogue","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dkaa095","article-title":"In vitro synergy of ceftolozane\/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa","volume":"75","author":"Cuba","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1128\/AAC.00589-13","article-title":"In vitro activity of fosfomycin against a collection of clinical Pseudomonas aeruginosa isolates from 16 Spanish hospitals: Establishing the validity of standard broth microdilution as susceptibility testing method","volume":"57","author":"Morosini","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Gatti, M., Giannella, M., Rinaldi, M., Gaibani, P., Viale, P., and Pea, F. (2022). Pharmacokinetic\/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and\/or Hospital-Acquired Pneumonia. Antibiotics, 11.","DOI":"10.3390\/antibiotics11121739"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10096-007-0456-4","article-title":"Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin","volume":"27","author":"Falagas","year":"2008","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ijantimicag.2007.07.023","article-title":"Antimicrobial activity of fosfomycin against multidrug-resistant Pseudomonas aeruginosa in vitro","volume":"30","author":"Kobayashi","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF01709477","article-title":"In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa","volume":"16","author":"Tessier","year":"1997","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s101560200004","article-title":"Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay","volume":"8","author":"Okazaki","year":"2002","journal-title":"J. Infect. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000007121","article-title":"Surveillance of Pseudomonas aeruginosa in intensive care units: Clusters of nosocomial cross-infection and encounter of a multiple-antibiotic resistant strain","volume":"44","author":"Traub","year":"1998","journal-title":"Chemotherapy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF01691312","article-title":"Study of Pseudomonas aeruginosa serotype O12 isolates with a common antibiotic susceptibility pattern","volume":"15","author":"Talarmin","year":"1996","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jac\/dkw456","article-title":"Synergistic activity of fosfomycin, beta-lactams and peptidoglycan recycling inhibition against Pseudomonas aeruginosa","volume":"72","author":"Zamorano","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yang, X., Domalaon, R., Lyu, Y., Zhanel, G.G., and Schweizer, F. (2018). Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant Pseudomonas aeruginosa. J. Clin. Med., 7.","DOI":"10.3390\/jcm7070158"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2147\/IDR.S207569","article-title":"In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections","volume":"12","author":"Gopichand","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"788-e5","DOI":"10.1016\/j.cmi.2020.11.029","article-title":"Evaluation of the commercial AD fosfomycin test for susceptibility testing of multidrug-resistant Enterobacterales and Pseudomonas aeruginosa","volume":"27","author":"Parisio","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10-1128","DOI":"10.1128\/AAC.00126-19","article-title":"Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-beta-Lactamase","volume":"63","author":"Albiero","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3934\/microbiol.2020011","article-title":"The combined antimicrobial activity of citrus honey and fosfomycin on multidrug resistant Pseudomonas aeruginosa isolates","volume":"6","author":"Abdelhady","year":"2020","journal-title":"AIMS Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Croughs, P.D., Konijnendijk-de Regt, M., and Yusuf, E. (2022). Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.02504-21"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10-1128","DOI":"10.1128\/JCM.01121-20","article-title":"Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates","volume":"58","author":"Smith","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e0144621","DOI":"10.1128\/AAC.01446-21","article-title":"Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and Enterobacterales","volume":"66","author":"Zheng","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","article-title":"Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa","volume":"11","author":"Holger","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Riano-Moreno, J., Romero-Leiton, J.P., and Prieto, K. (2022). Contribution of Governance and Socioeconomic Factors to the P. aeruginosa MDR in Europe. Antibiotics, 11.","DOI":"10.3390\/antibiotics11020212"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e0021622","DOI":"10.1128\/aac.00216-22","article-title":"OXA-48-Like beta-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline","volume":"66","author":"Boyd","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10-1128","DOI":"10.1128\/mSystems.00524-19","article-title":"Regulation of AmpC-Driven beta-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling","volume":"4","author":"Torrens","year":"2019","journal-title":"mSystems"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Laudy, A.E., Rog, P., Smolinska-Krol, K., Cmiel, M., Sloczynska, A., Patzer, J., Dzierzanowska, D., Wolinowska, R., Starosciak, B., and Tyski, S. (2017). Prevalence of ESBL-producing Pseudomonas aeruginosa isolates in Warsaw, Poland, detected by various phenotypic and genotypic methods. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180121"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Horcajada, J.P., Montero, M., Oliver, A., Sorli, L., Luque, S., Gomez-Zorrilla, S., Benito, N., and Grau, S. (2019). Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin. Microbiol. Rev., 32.","DOI":"10.1128\/CMR.00031-19"},{"key":"ref_37","first-page":"19","article-title":"Deciphering pharmacokinetics and pharmacodynamics of fosfomycin","volume":"32","year":"2019","journal-title":"Rev. Espa\u00f1ola Quimioter."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10-1128","DOI":"10.1128\/AAC.00476-17","article-title":"In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","article-title":"What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review","volume":"58","author":"Sumi","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/jac\/dky045","article-title":"Elucidation of the pharmacokinetic\/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model","volume":"73","author":"Bilal","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00752-15","article-title":"Pharmacodynamics of fosfomycin: Insights into clinical use for antimicrobial resistance","volume":"59","author":"Drusano","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Gatti, M., Virgili, G., Cojutti, P.G., Gaibani, P., Conti, M., Sturiale, C., Pea, F., and Viale, P. (2022). Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime-Avibactam-Based Regimens: A Report of Two Cases. Microorganisms, 10.","DOI":"10.3390\/microorganisms10010154"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkq070","article-title":"Extracellular concentrations of fosfomycin in lung tissue of septic patients","volume":"65","author":"Matzi","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Konig, C., Martens-Lobenhoffer, J., Czorlich, P., Westphal, M., Bode-Boger, S.M., Kluge, S., and Grensemann, J. (2023). Cerebrospinal fluid penetration of fosfomycin in patients with ventriculitis: An observational study. Ann. Clin. Microbiol. Antimicrob., 22.","DOI":"10.1186\/s12941-023-00572-4"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/jac\/dkh158","article-title":"Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis","volume":"53","author":"Pfausler","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jac\/dkg187","article-title":"Target site penetration of fosfomycin in critically ill patients","volume":"51","author":"Joukhadar","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/AAC.47.1.371-374.2003","article-title":"Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome","volume":"47","author":"Legat","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1128\/AAC.49.11.4448-4454.2005","article-title":"Antibiotic abscess penetration: Fosfomycin levels measured in pus and simulated concentration-time profiles","volume":"49","author":"Sauermann","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/jac\/dkp230","article-title":"High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection","volume":"64","author":"Schintler","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_50","unstructured":"ECDC (2019). Healthcare-Associated Infections in Intensive Care Units, ECDC Annual Epidemiological Report for 2017."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"01682-18","DOI":"10.1128\/AAC.01682-18","article-title":"The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model","volume":"62","author":"Drusano","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"02627-17","DOI":"10.1128\/AAC.02627-17","article-title":"Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model","volume":"62","author":"Louie","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa","volume":"220","author":"Zeiser","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Anastasia, A., Bonura, S., Rubino, R., Giammanco, G.M., Micciche, I., Di Pace, M.R., Colomba, C., and Cascio, A. (2023). The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy. Antibiotics, 12.","DOI":"10.3390\/antibiotics12060971"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Burastero, G.J., Orlando, G., Santoro, A., Menozzi, M., Franceschini, E., Bedini, A., Cervo, A., Faltoni, M., Bacca, E., and Biagioni, E. (2022). Ceftazidime\/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature. Antibiotics, 11.","DOI":"10.3390\/antibiotics11081007"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Gatti, M., Viaggi, B., Rossolini, G.M., Pea, F., and Viale, P. (2021). An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients. Antibiotics, 11.","DOI":"10.3390\/antibiotics11010033"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14787210.2021.1932463","article-title":"Intravenous fosfomycin for the treatment of patients with bone and joint infections: A review","volume":"20","author":"Tsegka","year":"2022","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"732.e1","DOI":"10.1016\/j.cmi.2016.05.004","article-title":"Time trends in the aetiology of prosthetic joint infections: A multicentre cohort study","volume":"22","author":"Benito","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Hirakawa, H., Kurabayashi, K., Tanimoto, K., and Tomita, H. (2018). Oxygen Limitation Enhances the Antimicrobial Activity of Fosfomycin in Pseudomonas aeruginosa Following Overexpression of glpT Which Encodes Glycerol-3-Phosphate\/Fosfomycin Symporter. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.01950"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Davey, P., Wilcox, M., Irving, W., Thwaites, G., Davey, P., Wilcox, M.H., Irving, W., and Thwaites, G. (2015). Antimicrobial Chemotherapy, Oxford University Press.","DOI":"10.1093\/med\/9780199689774.001.0001"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1128\/AAC.39.5.1038","article-title":"Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm","volume":"39","author":"Kumon","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wang, L., Di Luca, M., Tkhilaishvili, T., Trampuz, A., and Gonzalez Moreno, M. (2019). Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.02522"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10096-014-2285-6","article-title":"Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin","volume":"34","author":"Mei","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1302\/2058-5241.4.180093","article-title":"Infection after fracture fixation","volume":"4","author":"Steinmetz","year":"2019","journal-title":"EFORT Open Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/adc.88.6.512","article-title":"Fosfomycin for the initial treatment of acute haematogenous osteomyelitis","volume":"88","author":"Corti","year":"2003","journal-title":"Arch. Dis. Child"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7150\/jbji.27811","article-title":"Daptomycin Plus Fosfomycin as Salvage Therapy in a Difficult-to-Treat Total Femoral Replacement Infection","volume":"3","author":"Luengo","year":"2018","journal-title":"J. Bone Jt. Infect."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF01644014","article-title":"Adjuvant fosfomycin medication in chronic osteomyelitis","volume":"17","author":"Meissner","year":"1989","journal-title":"Infection"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/ajhp\/zxab294","article-title":"Intravenous fosfomycin as salvage therapy for osteomyelitis caused by multidrug-resistant Pseudomonas aeruginosa","volume":"78","author":"Wong","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"ofaa572","DOI":"10.1093\/ofid\/ofaa572","article-title":"Cure of Limb-Threatening XDR Pseudomonas aeruginosa Infection: Combining Genome Sequencing, Therapeutic Drug Level Monitoring, and Surgical Debridement","volume":"8","author":"Narayanasamy","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jac\/dkr466","article-title":"Fosfomycin: Evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens","volume":"67","author":"Karageorgopoulos","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01871127","article-title":"Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women","volume":"15","author":"Hermans","year":"1993","journal-title":"Pharm. World Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1128\/AAC.38.11.2612","article-title":"Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women","volume":"38","author":"Elhanan","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","first-page":"729","article-title":"Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women","volume":"52","author":"Christiaens","year":"2002","journal-title":"Br. J. Gen. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/43.suppl_1.67","article-title":"A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection","volume":"43","author":"Iravani","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki280","article-title":"Bacterial prostatitis due to Pseudomonas aeruginosa harbouring the blaVIM-2 metallo-beta-lactamase gene from Saudi Arabia","volume":"56","author":"Guerin","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2\/3 Randomized Trial","volume":"69","author":"Kaye","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1128\/AAC.00402-12","article-title":"Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms","volume":"56","author":"Neuner","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Rodriguez-Rojas, A., Macia, M.D., Couce, A., Gomez, C., Castaneda-Garcia, A., Oliver, A., and Blazquez, J. (2010). Assessing the emergence of resistance: The absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010193"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jgar.2023.03.010","article-title":"Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry","volume":"33","author":"Zhanel","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/00365548.2011.616221","article-title":"Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteria","volume":"44","author":"Dinh","year":"2012","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000449422","article-title":"Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes","volume":"62","author":"Giancola","year":"2017","journal-title":"Chemotherapy"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.ijantimicag.2007.06.015","article-title":"Pseudomonas aeruginosa bloodstream infections: How should we treat them?","volume":"30","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1128\/AAC.00349-11","article-title":"Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmi.2016.12.005","article-title":"Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature","volume":"23","author":"Grabein","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1017\/S0950268810003055","article-title":"Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: Risk factors and mortality","volume":"139","author":"Tumbarello","year":"2011","journal-title":"Epidemiol. Infect."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2009.03.009","article-title":"Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: A systematic review of microbiological, animal and clinical studies","volume":"34","author":"Falagas","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/QCO.0000000000000418","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in central nervous system infections","volume":"31","author":"Nau","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000222045","article-title":"A study of the levels of fosfomycin in the cerebrospinal fluid in adult meningitis","volume":"23","author":"Drobnic","year":"1977","journal-title":"Chemotherapy"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e00451","DOI":"10.1016\/j.idcr.2018.e00451","article-title":"Ceftolozane-tazobactam and Fosfomycin for rescue treatment of otogenous meningitis caused by XDR Pseudomonas aeruginosa: Case report and review of the literature","volume":"14","author":"Frattari","year":"2018","journal-title":"IDCases"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","article-title":"A typology of reviews: An analysis of 14 review types and associated methodologies","volume":"26","author":"Grant","year":"2009","journal-title":"Health Inf. Libr. J."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/12\/1653\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:28:45Z","timestamp":1760131725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/12\/1653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":94,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["antibiotics12121653"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12121653","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}